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HIV-1 broadly neutralizing antibodies are desired for their therapeutic potential and as 
templates for vaccine design. Such antibodies target the HIV-1-envelope (Env) trimer, 
which is shielded from immune recognition by extraordinary glycosylation and sequence 
variability. Recognition by broadly neutralizing antibodies thus provides insight into how 
antibody can bypass these immune-evasion mechanisms. Remarkably, antibodies 
neutralizing >25% of HIV-1 strains have now been identified that recognize all major 
exposed surfaces of the prefusion-closed Env trimer. Here we analyzed all 206 broadly 
neutralizing antibody-HIV-1 Env complexes in the PDB with resolution suitable to define 
their interaction chemistries. These segregated into 20 antibody classes based on ontogeny 
and recognition, and into 6 epitope categories (V1V2, glycan-V3, CD4-binding site, silent 
face center, fusion peptide, and subunit interface) based on recognized Env residues. We 
measured antibody neutralization on a 208-isolate panel and analyzed features of paratope 
and B cell ontogeny. The number of protruding loops, CDR H3 length, and level of somatic 
hypermutation for broadly HIV-1 neutralizing antibodies were significantly higher than 
for a comparison set of non-HIV-1 antibodies. For epitope, the number of independent 
sequence segments was higher (P < 0.0001), as well as the glycan component surface area (P 
= 0.0005). Based on B cell ontogeny, paratope, and breadth, the CD4-binding site antibody 
IOMA appeared to be a promising candidate for lineage-based vaccine design. In terms of 
epitope-based vaccine design, antibody VRC34.01 had few epitope segments, low epitope-
glycan content, and high epitope-conformational variability, which may explain why 
VRC34.01-based design is yielding promising vaccine results. 
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Significance 
Over the last decade, structures of broadly neutralizing antibodies have been determined, 
encompassing all major exposed surfaces on the prefusion-closed HIV-1-envelope (Env) trimer. 
To provide insight into how the immune system generated these antibodies along with molecular 
detail of their recognition, we surveyed known Env-antibody structures. We found that (i) 
broadly neutralizing antibodies recognized sequence variability and glycan at frequencies similar 
to their average occurrence on the Env-trimer surface, (ii) almost two-thirds of the paratopes 
utilized protruding loops, which were otherwise less common; and (iii) the broadest HIV-1-
neutralizing antibodies had high levels of SHM, and the most potent unusual recombination, but 
antibodies with more reproducible B cell ontogenies still neutralized broadly, and these may be 
better templates for re-elicitation. 
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Antibodies against HIV-1 that neutralize a significant fraction of the diverse primary 
isolates that typify HIV-1 transmission are highly sought. These antibodies target the HIV-1 
envelope (Env) trimer, which is comprised of gp120 and gp41 subunits and shielded from 
immune recognition by extraordinary glycosylation (1), sequence variability (2), and 
conformational masking (3). A decade ago, only four such broadly neutralizing antibodies had 
been identified. However, in 2009, the identification by B cell culture of antibody PG9 (along 
with a somatic variant PG16) (4) and in 2010 the identification by probe-based sorting of 
antibody VRC01 (along with somatic variants VRC02 and VRC03) (5) initiated an outbreak of 
discovery, with dozens of broadly neutralizing antibodies identified by culture or probe-based 
sorting of B cells from HIV-1 infected donors (reviewed in (6)). 
Importantly, structures for many of these antibodies in complex with HIV-1 Env have 
been determined, which link antibody function (breadth and potency of neutralization) with 
molecular features of antibody recognition (paratope) and chemical details of Env-recognized 
site (epitope). For example, structures of PG9 with scaffolded V1V2 regions of Env (7) and also 
with Env trimer (8) have revealed a protruding anionic tyrosine-sulfated loop penetrating the 
glycan shield to interact with a conserved cationic site on V2; similarly structures of VRC01 
with core gp120 (9) or with a fully glycosylated Env trimer (10) have revealed how SHM-based 
optimization of interactions – especially those involving glycan – allows for broad recognition of 
the CD4-binding site. Most recently, the structure of antibody VRC-PG05 in complex with a 
glycosylated Env core (11) has shown that even the highly glycosylated center of the Env “silent 
face” could be recognized by broadly neutralizing antibodies. 
The structure of VRC-PG05 in complex with Env completes recognition by structurally 
characterized antibody of all major exposed surfaces on the prefusion-closed HIV-Env trimer. 
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Here we take advantage of this completion to perform a structure-based survey of all antibody-
HIV-1 Env structures in the Protein Data Bank (PDB). We limited analyses to structures of 
human antibodies (with neutralization breadth > 25%) in complex with epitopes on the 
prefusion-closed Env trimer with resolutions sufficient to define side chain orientation and 
interactions. The focus on the prefusion-closed conformation of Env alleviated issues of 
conformational masking and enabled comparisons on a single structural entity. We further 
classified structures by antibody class (B cell ontogeny and structural mode of recognition) to 
unique classes and used a bottom-up classification based on residues of each epitope to define 
epitope categories. We measured antibody neutralization on a diverse cross-clade panel of 208 
HIV-1 isolates and correlated structural features of epitope and paratope with functional 
characteristics of neutralization breadth and potency. We also analyzed paratopes for ease of 
lineage re-elicitation and epitopes for ease of mimicry. Overall, our structural survey of HIV-1 
antibodies targeting the prefusion-closed Env trimer delineates categories, identifies underlying 
relationships between structural properties of paratope and epitope and functional properties of 
neutralization, and suggests favorable candidates for vaccine design. 
 
Results 
Broadly neutralizing antibodies that recognize the prefusion-closed Env trimer segregate 
into 20 classes and 6 categories 
The PDB contains over 200 coordinate sets for human antibodies in complex with 
various portions of HIV-1 Env, ranging from fully glycosylated Env trimers to core gp120, 
scaffolded domains, representative N-linked glycans, and peptide fragments (Dataset S1). We 
chose to limit our analysis to structures with resolutions sufficient to define chemistry of 
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interaction: for X-ray crystal structures, we used a resolution limit of 3.9 Å, and for cryo-electron 
microscopy structures, we used a resolution limit of 4.5 Å. Also, we chose to limit our analysis 
to antibodies that neutralize at least 25% of HIV-1 at 50 μg/ml, as measured in a cross-clade 
panel of at least 100 isolates. Finally, to alleviate issues of conformation, we limited our analysis 
to only those antibodies that recognize the prefusion-closed conformation of Env as this allowed 
us to focus on a single structural entity: the Env trimer in its prefusion-closed state. 
We next used similarity in B cell ontogeny and structural mode of recognition to classify 
these PDBs into antibody classes (12) (Table 1). While some antibody classes have only been 
found in a single donor to date (e.g., CH103, VRC38), other classes have been found in more 
than one donor (e.g. VRC01, 8ANC131). The largest class involved the VRC01 class (13), with 
53 PDBs describing 33 antibodies. Antibodies recognizing glycan-V3, derived primarily from 
classes that have only a single known clonal lineage, although PGT121 and BG18 lineages do 
share the same D3-3 gene and mode of recognition (14, 15). For antibodies recognizing the spike 
apex, prior analyses placed antibody lineages PG9, PGT145 and CH01 in the same class (7). 
While structural information showed parallel strand recognition for PG9 and CH03 indicating 
similar classes (16), structures of PGT145 with Env trimer (17, 18) indicated loop insertion into 
a trimeric hole at the spike apex, and hence a distinct mode of recognition and class for PGT145. 
We used the name of the first identified antibody in each antibody class as the name of the class. 
We selected a structural representative antibody for each class based on the most 
informative structure (for example, choosing an antibody-Env trimer complex over the same 
antibody with a deglycosylated core gp120) (Fig. 1A) Based on the 20 representative antibody-
antigen complex structures, we defined epitope residues on the prefusion-closed Env trimer by 
buried surface area calculations (see methods). For 2G12, the most complete antibody-Env 
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complexes defined interactions with only a few N-linked glycans (19); therefore, we used 
published biochemical studies to define the 2G12 epitope residues (20). Next, we carried out 
hierarchical clustering of epitope residues, which clustered the 20 antibody epitopes into 6 
categories (Fig. 1A,B). Three of the categories had been previously described: V1V2, glycan-V3 
and CD4-binding site, and each of these categories encompassed at least three different antibody 
classes. Three additional categories were identified, including the “silent face center” (with 
antibody VRC-PG05), “fusion peptide” (with antibodies PGT151 and VRC34), and “subunit 
interface” (with antibodies 35O22 and 8ANC195). Beyond shared epitope residues, each of the 
categories did appear to have specific characteristics. For example, smFRET measurements 
define three prefusion states (states 1-3) of the Env trimer and found broadly neutralizing 
antibodies to preferentially recognize state 1 (21); only two antibodies, VRC34.01 (22) and 
PGT151 (personal communications, Walther Mothes), have thus far been found to shift the 
smFRET population to state 2, and both were assigned to the same epitope category. Thus, our 
structural analysis defined six categories of broadly neutralizing antibodies, and antibodies in 
each category generally shared similar characteristics. 
 
Neutralization characteristics for 20 antibody classes 
As the most important functional property of the 20 antibody classes is their ability to 
neutralize diverse HIV-1 isolates, we felt it important to measure accurately this feature in a way 
that allowed comparison between different antibodies. We thus measured both neutralization 
breadth and potency for the representative member of each class on a diverse cross-clade panel 
of 208 HIV-1 isolates (23) (Fig. 2A,B, Data Set S2). For functional representative, we chose the 
antibody-class member with highest neutralization breadth. For the PGT121 class, we chose 
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antibody 10-1074 (14); for the VRC01 class, we chose antibody N6 (24); and for the 8ANC131 
class we chose antibody CH235.12 (25). Notably, the newly measured median neutralization 
IC50 generally differed by less than 2 fold from prior reported values (5, 7, 11, 22, 24-40), with 
the breadth for all 20 classes averaging 56.7%, with an average geometric mean IC50 of 0.27 
μg/ml. 
 
B cell ontogenies, paratopes, and epitopes of antibodies recognizing the prefusion-closed 
Env trimer 
 B cell ontogenies involve the recombination events that lead to creation of the ancestor B 
cell for each lineage, as well as SHM that lead to mature antibody clones. To estimate elicitation 
likelihoods related to recombination and SHM, we extracted CDR H3 length and V-gene SHM 
(Fig. 2C). We observed that the average CDR H3 length and heavy chain SHM of the 20 HIV-1 
broadly neutralizing antibodies were higher than those of next generation sequencing (NGS) 
reads from three healthy donors (P<0.0001) (25). 
 We also extracted critical features of the paratope (Fig. 2D). We selected a measure 
related to recognition mode (number of protruding antibody loops) and a second measure related 
to recognition extent (the surface area of the interacting paratope). Thirteen of the 20 antibodies 
utilized protruding loops in recognition, although this feature was less common in non-HIV-1 
antibodies (as defined on a set of 81 non-HIV-1 antibody-antigen structures, see Datasets S3 and 
S4). The paratope surface areas were almost twice as high as observed with non-HIV-1 
antibodies (P<0.0001), and this may relate to glycan interactions, as antibodies with 
deglycosylated cores generally showed lower interactive surface areas. 
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 For epitope, we measured several features including sequence conservation, extent of 
glycan contribution, number of independent sequence elements in each epitope, and the 
structural variability of the epitope (Fig. 3A-D). For sequence conservation, epitopes of broadly 
neutralizing antibodies (75% conservation) were similar to the average conservation of the 
closed trimer (69%). For glycan, we observed the average contribution to epitope surface area 
(45%) was similar to the surface area contribution of MAN5 glycans to the overall Env trimer 
surface area (53%). Also, we observed that the average epitope glycan composition (P=0.0005), 
total epitope surface area (P<0.0001), and number of epitope segments (P<0.0001) of the 20 
HIV-1 broadly neutralizing antibodies were higher than those of non-HIV-1 antibodies (Datasets 
S3 and S4; for glycan composition specifically, the comparison was done with a non-HIV-1 
glycoprotein set with 16 antibody antigen complexes, see Methods and Dataset 5). It may be that 
features common in HIV-1 neutralizing antibodies, but generally rare, provide insight into 
recognition constraints: in this case suggesting that HIV broadly neutralizing antibodies were 
selected specifically to overcome sequence variability and glycosylation. 
 
Underlying relationships between neutralization, paratope and epitope 
 To provide insight into other features specific to these HIV-1 neutralizing antibodies, we 
correlated neutralization with epitope and paratope features to reveal underlying relationships 
(Fig. 4A). Although a number of features correlated with p-values of less than 0.05, when 
corrected for multiple comparison, few correlations were significant. Significant correlations 
included the expected positive correlation between surface area of paratope and surface area of 
epitope (P < 0.0001, r = 0.9845) (Fig. 4B) and a negative correlation between protein and glycan 
surface areas (P = 0.0002, r = -0.8413) (Fig. 4C). This negative correlation suggests antibodies to 
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have an overall surface area that can comprise either protein or glycan; thus, a glycan-focused 
antibody generally has lower protein-interactive surface than a protein-focused antibody, and vice 
versa. 
 Other correlations did not achieve statistical significance, but were potentially revealing. 
For example, we observed antibody neutralization breadth to correlate positively with degree of 
heavy chain SHM (P = 0.0510, r = 0.4538) and buried protein-epitope surface area (P = 0.0079, r 
= 0.5892) and negatively with degree of epitope glycan (P = 0.0105, r = -0.6579) (Fig. 4D), 
indicating that while antibody recognition can include glycan, this nevertheless reduces breadth. 
Meanwhile sequence conservation correlated with size of the epitope (P = 0.0254, r = 
0.6961)/paratope (P = 0.0211, r = 0.7110) (Fig. 4E), suggesting that one way to overcome 
variation is by reducing the area of recognized surface. We also noticed that the broadest HIV-1-
neutralizing antibodies had high levels of SHM and the most potent had unusual CDR H3s (Fig. 
2). Overall, these observations suggested both the frequency and the extent that neutralizing 
antibodies targeting the prefusion-closed Env trimer utilize protruding loops, unusual 
recombination, and extensive SHM to overcome immune evasion mechanism of extraordinary 
glycosylation and high sequence variability. 
 
Re-elicitation: Antibody-lineage based vaccine design 
 We also analyzed antibodies to identify which B cell ontogenies might be most easily re-
elicited by antibody-lineage based vaccine design. Such design is premised on the re-elicitation 
of antibodies with similar ontogenies, through priming of ancestor B cells and induction of their 
maturation (16, 41, 42). Two factors affect re-elicitation: the likelihood that an appropriate 
recombination event produces an appropriate unmutated common ancestor (UCA) and the 
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likelihood that this UCA will mature through processes of SHM to achieve similar functional 
properties of neutralization. The former is affected by prevalence of appropriate V-genes and by 
the contribution to the paratope of CDR H3 features such as D-gene and N-nucleotide addition, 
which we calculated for each of the 20 classes of neutralizing antibodies (Fig. 5). We also 
calculated features of SHM, such as the percent of the V gene-contributed paratope surface 
altered by SHM or the prevalence of rare mutations (43). Although some of the broadest and 
most potent antibodies had features that lowered the probability of their re-elicitation, there were 
antibody classes with less rare SHM and CDR H3 characteristics such as IOMA, as well as 
antibodies like PG9 with extensive D-gene contributions to antigen recognition that might be re-
elicited with greater ease. 
 
Discussion 
The completion by antibody VRC-PG05 of structural characterization of the recognition 
by broadly neutralizing antibodies of all major exposed surfaces on the prefusion-closed Env 
trimer enables both comprehensive and aggregate-level analyses: Relative to paratope, we could 
address which characteristics allow for broad recognition of the glycosylated and sequence-
variable Env trimer, and relative to the Env trimer surface, we could address which features were 
recognized and which were avoided. For paratope, our results indicated protruding loops and 
extensive SHM to dominate recognition (an observation previously reported by Klein and 
colleagues (44) utilizing a less complete set of HIV-1-directed antibodies), although antibodies 
with more common features could be found. For epitope, our results indicate both glycan and 
sequence variation to be recognized by antibody, which may relate to the extent that these 
features dominate the surface of the prefusion-closed Env trimer. 
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While our focus on the prefusion-closed trimer allowed us to relate properties of 
recognized epitopes to average properties of the Env trimer in a specific conformation, this focus 
led to the omission from our analysis of an important class of broadly neutralizing antibodies, 
those that target the membrane-proximal external region (MPER) (Fig. S1 and Table S2). MPER 
antibodies generally show low levels of recognition of the native Env trimer (45) and have thus 
been proposed to recognize Env trimer in a different conformation (46). In addition to 
differences in conformation of Env recognized, MPER antibodies also target regions of Env with 
significantly lower glycan and sequence variability. Thus, the immune-evasion mechanisms that 
shield the MPER appear to differ from those shielding the prefusion-closed Env trimer, and the 
antibody mechanisms that allow for recognition of the MPER likely differ as well from those 
that allow recognition of the closed Env trimer. 
In terms of antibody templates most favorable for vaccine design, our analysis suggested 
the IOMA lineage as being most favorable for re-elicitation by antibody lineage-based 
approaches due to the lack of unusual features in its B cell ontogeny. Furthermore, in comparison 
with VRC01 class antibodies, IOMA may overcome the N276-glycan barrier more readily: CDR 
L1 in IOMA (and in most other antibodies from VL2-23 and related germline genes) has a short 
α-helix that can accommodate the N276 glycan with fewer mutations than required by VRC01 
class antibodies (47). In terms of features most favorable to epitope-based vaccine design, we 
note that antibody VRC34.01 had few epitope segments, low epitope-glycan content, and high 
epitope-conformational variability (48). These features may suggest that vaccine design based on 
the epitope of antibody VRC34.01 may be especially promising. Indeed, we recently achieved 
the elicitation of antibodies in mice, guinea pigs and rhesus macaques that neutralized diverse 
HIV-1 Env isolates through immunogen design based on the epitope of VRC34.01 (49). Thus, in 
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addition to revealing features of paratope and epitope that allow for immune recognition of the 
prefusion closed spike, the structural survey also provides insight into which antibody templates 
are most suitable for vaccine design. 
 
Materials and Methods 
Structural Dataset and Selection of Structural Representative for Each of the 20 Unique 
HIV-1 Antibody Classes. All the antibody-antigen complex structures were collected from 
Protein Data Bank (PDB) (50) using the key words “HIV-1 antibody” on 28 February 2018. 
Structures that contain antibody alone were excluded. Non-human and synthetic antibodies were 
also excluded. The final comprehensive list of current deposited HIV-1 human antibody-antigen 
complex structures is provided in Dataset S1. Only the antibodies that target envelope trimer 
neutralize Tier 2 HIV-1 isolates were considered. To focus on broadly neutralizing HIV-1 
antibodies, a neutralizing breadth cutoff of >25% was also used. Based on ontogenies in separate 
donors, we defined 20 unique classes that recognize the prefusion-closed Env trimer (Fig. 1A). 
For each antibody class, we selected the most informative structure based on the following 
criteria: 1) Resolution cutoff for X-ray crystal structures < 3.9 Å and < 4.5 Å for cryo-EM 
structures, allowing for a margin of 0.5 Å in resolution if a high resolution antibody-epitope 
complex were also available. 2) The complex structure of the trimer with highest resolution was 
selected, followed by glycosylated monomer, by deglycosylated monomer, or by scaffolded 
domain with highest resolution. The final PDB IDs we selected included 5V8L (18) (for 
PGT145), 3U2S (7) (for PG9), 5VGJ (34) (for VRC38.01), 5CEZ (51) (for 3H+109L and 
35O22), 5ACO (52) (for PGT128), 4JM2 (53) (for PGT135), 1OP5 (19) (for 2G12), 4YE4 (for 
HJ16), 5T3Z (47) (for IOMA), 5F9O (25) (for CH235.09), 5FYJ (10) (for VRC01), 4YDJ (32) 
(for VRC13.01), 5VN8 (54) (for b12), 4JAN (28) (for CH103), (32) 4YDK (for VRC16.01), 
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6BF4 (11) (for VRC-PG05), 5FUU (55) (for PGT151), 5I8H (22) (for VRC34.01), and 5CJX 
(56) (for 8ANC195). 
Epitope and Paratope Buried Surface Area Calculations. The buried surface area between 
antibody and antigen was calculated using program NACCESS (57). The epitope residues and 
paratope residues for each antibody were defined as residues with non-zero buried surface area. 
For 2G12, the epitope residues were defined as glycans N295, N332, and N392, based on (20). 
Structural Definition of HIV-1 Env Broadly Neutralizing Antibody Categories. The 
structural representative of the 20 unique antibodies were clustered using hierarchical clustering, 
with the distance between each of the antibody is defined as 1    


 , where 

 is the number of 
overlapping epitope residues, and 

 is the number of epitope residues for the antibody with the 
least number of epitope residues of the two. 
Display of Epitope Residues on Prefusion-Closed HIV-1 Env. The BG505 SOSIP trimer 
structure (PDB:5FYL) was used as the template with each glycan (with the addition of glycans 
241 and 332) modeled as MAN5. Amino acid and glycan epitope residues were colored based on 
the structurally defined antibody category. Epitope residues with more than 5 Å C-alpha 
deviation from PDB:5FYL were excluded. For residue positions shared in epitopes from multiple 
antibody categories, the color of the antibody category with the antibody that has the largest 
epitope surface area was used. 
Antibody Expression and Purification. The 20 representative antibody heavy and light chain 
expression constructs were synthesized (Gene Universal Inc., Newark, DE) and cloned into 
pVRC8400 expressing vector. For antibody protein expression, 1.5 ml of Turbo293 transfection 
reagent (Speed BioSystems) were mixed into 25 ml Opti-MEM medium (Life Technology) and 
incubated for 5 min at room temperature. 500 μg of plasmid DNAs (250 heavy chain and 250 μg 
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of light chain) were mixed into 25 ml of Opti-MEM medium in another tube. Then the diluted 
Turbo293 were added into Opti-MEM medium containing plasmid DNAs. Transfection reagent 
and DNA mixture was incubated for 15 min at room temperature, and added to 400 ml of 
Expi293 cells (Life Technology) at 2.5 million cells/ml. The transfected cells were cultured in 
shaker incubator at 120 rpm, 37 °C, 9% CO2 overnight. On the next day of transfection, 40 ml of 
AbBooster medium (ABI scientific) were added to each flask of transfected cells and the flasks 
were transferred to shaker incubators at 120 rpm, 33 °C, 9% CO2 for additional 5 days. At 6 
days post transfection, antibodies in clarified supernatants were purified over 3 ml Protein A (GE 
Health Science) resin in columns. Antibody was eluted with IgG elution buffer (Pierce), 
immediately neutralized with one tenth volume of 1M Tris-HCL pH 8.0. The antibodies were 
then buffer exchanged in PBS by dialysis, adjusted concentration to 1.0 mg/ml and filtered (0.22 
μm) for neutralization assays (58) (45). 
Virus Neutralization. Single-round-of-replication Env pseudoviruses were prepared, titers were 
determined, and the pseudoviruses were used to infect TZM-bl target cells as described 
previously in an optimized and qualified automated 384-well format (59). Briefly, antibodies 
were serially diluted, a constant amount of pseudovirus added, and plates incubated for 60 
minutes; followed by addition of TZMbl cells which express luciferase upon viral infection. The 
plates were incubated for 48 hours and then lysed, and luciferase activity measured. Percent 
neutralization was determined by the equation: (virus only)-(virus+antibody)/(virus only) 
multiplied by 100. Data are expressed as the antibody concentration required to achieve 50% 
neutralization (IC50) and calculated using a dose-response curve fit with a 5-parameter nonlinear 
function. We used a previously described panel (5, 34, 60) of 208 geographically and genetically 
diverse Env pseudoviruses representing the major subtypes and circulating recombinant forms. 
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The IC50 values reported here are from the complete set of 208 viruses run at the VRC. In some 
cases, multiple runs were averaged. The values used here differed slightly, generally within 2 
fold of previous median IC50, from previously reported values in references (5, 7, 11, 22, 24-40). 
The differences have two sources: in earlier publications, the panels contained between 178 and 
198 of the 208 viruses; and because the neutralization IC50 values are known to vary up to 3-fold 
between repeat assays, as documented in (59). 
CDR H3 Length, Germline Gene Assignment, N-Insertion, and SHM Calculations. 
Antibody CDR H3 length, germline gene assignment, N-insertion, and SHM Calculation was 
performed using the IMGT/HighV-QUEST webserver (http://www.imgt.org/HighV-QUEST/). 
Number of Protruding Loops. CDR loops (i.e. CDR L1, CDR L2, CDR L3, CDR H1, CDR 
H2, CDR H3) were inspected manually, and two criteria were used in defining whether a CDR 
loop would be considered as protruding: 1) the loop extends at least 5Å beyond a plane defined 
by the average extent of the six antibody CDRs, and 2) the loop contacts with HIV epitope 
residues. 
Epitope Conservation Calculations. The conservation of each HIV-1 Env residue was 
calculated using the entropy function of the R package bio3d (H.norm column), with the addition 
of glycan as residue type. The calculation was based on the filtered web alignment of the year 
2016 from the Los Alamos HIV sequence database (http://www.hiv.lanl.gov/). The epitope 
conservation was defined as the average conservation for each residue, weighted by epitope 
surface area. The average Env surface conservation was defined as the average conservation for 
each Env residue, weighted by accessible surface area as determined by NACCESS (57). 
Average Glycan Surface Calculations. The glycan surface area of the HIV-1 Env prefusion-
closed trimer was calculated applying a two-step procedure. First, we approximated the 
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accessible surface area (ASA), using NACCESS program (57) with the default radius of 1.4 Å, 
for all protein as well as glycan residues based on a molecular dynamics simulation with a 500-
nanosecond timescale (10). Second, we determined the percentage of the glycan surface area, by 
dividing the ASA of glycan residues by the sum of the ASAs of protein and glycan residues. 
Number of Epitope Segment Calculations. The number of epitope segment is defined as 
number of continuous stretches on epitope residues, allowing skipping of one to two residues, 
which in total have an epitope surface area of greater than the specified threshold (25Å2 or 100 
Å2). 
Epitope Structural Variation Calculations. The epitope structural variation for each antibody 
class was determined by the averaged root-mean-square-deviation of recognized epitope amino 
acid residues computed pairwise among category members and the unliganded structure (PDB 
ID: 4ZMJ) (33) using PyMOL software. Antibody 2G12 conformational variability was not 
calculated due to lack of amino acid epitope residues. 
Correlation Analyses. Pearson correlation for every pair of antibody properties listed in Fig. 2 
and 3 were calculated. b12 class was not included in the correlation calculation as b12 was 
derived from phage display. For correlations involving total epitope surface, paratope surface, 
and number of epitope segment calculations, PG9, VRC38.01, PGT135, H16, CH235, 
VRC13.01, CH103, VRC16.01, and VRC-PG05 were excluded as their representative structures 
were determined with partial Env domain. For correlations involving epitope glycan 
composition, HJ16, CH235, VRC13.01, CH103, and VRC16.01 were excluded as their 
representative structures were determined with deglycosylated gp120 monomers. 
Non-HIV-1 Antibody Sequence Dataset and V-gene Frequency Estimation. Heavy and light 
chain NGS samples (43) from 454 pyrosequencing downloaded from Short Read Archive and 
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processed to calculate average SHM (Table S1A – S1C) and HV germline frequency (Table 
S1D). The next-generation sequencing (NGS) data from healthy donor performed with 5′ primer-
adapters should avoid bias of germline gene usage. All heavy chain reads shorter than 350 
nucleotides were removed, and all lambda and kappa chain reads longer than 300 nucleotides 
were kept. Germline genes were assigned to all filtered reads using IgBLAST (61). After 
assigned all reads, an in-house python script applied to process IgBLAST output, and non-IG 
sequences were removed. The variation between alleles were ignored, and we treated those 
alleles as identical VH gene. The VH gene frequency was calculated by the number of reads of 
VH germline divided by the total good IG sequences. 
SHM Rarity. Rarity score of a somatic hypermutation was calculated as 1-frequency of the 
SHM observed in gene-specific substitution profiles (43). SHMs with rarity score lower than 
0.5% were counted as rare SHMs. 
Non-HIV Antibody-Antigen Structural Dataset. A non-redundant non-HIV-1 Env 
antibody/antigen structural dataset was obtained from SAbDab (62), using the “Non-redundant 
search” function (Antibody identity = 90%, Antigen identity = 99% , for protein antigens, 
Resolution = 3.9 Å). The list was further filtered down by keeping only the human antibodies, 
and removing all HIV antibodies, resulting a total of 81 antibody/antigen complexes (Dataset 
S2). 
Non-HIV Glycoprotein Structural Dataset. To understand the difference of epitope glycan 
composition between HIV-1 antibodies and non-HIV-1 glycoprotein, a non-HIV-1 glycoprotein 
structural dataset was assembled with 16 antibodies complexed with one of the following 
glycoproteins: Ebola virus glycoprotein, Herpes simplex viruses -2 gD, Human 
Metapneumovirus fusion protein, Hepatitis C virus envelope glycoprotein E2 core, dengue virus 
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type 2 envelope glycoprotein, Human cytomegalovirus glycoprotein B, Respiratory syncytial F, 
Human cytomegalovirus pentamer, and influenza hemagglutinin (Dataset S5). To avoid the 
dataset over-represented by influenza hemagglutinin, only four structures (the number of 
structures for the next abundant antigen) were selected. Resolution cutoff for X-ray crystal 
structures < 3.9 Å and < 4.5 Å for cryo-EM structures. 
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Figure legends 
 
Fig. 1. 20 classes of broadly neutralizing antibodies recognize the prefusion-closed Env 
trimer and segregate into 6 categories based on the Env residues with which they interact. 
(A) All HIV-1 Env-antibody complexes structures in the PDB (Table S1) were assigned to 
classes (leftmost column, listed by the name of first reported antibody of the class) based on 
similarities in B cell ontogeny and mode of recognition, with a representative structure and PDB 
for the class (2nd and 3rd columns from left), which were chosen based on resolution and degree 
to which Env in the structure resembled prefusion-closed trimer; “*” indicate structures 
determined in gp120-core context; “#” indicates structures determined with V1/V2 scaffold; ”@” 
indicates glycan N295, N332, and N392 used for 2G12 epitope (see methods). (B) Prefusion-
closed Env trimer with molecular surface colored by categories defined in (A). Epitope residues 
shared by antibodies in separate classes were colored according to surface area and requirements 
for antibody binding. For example, glycan N276 has interactions with antibody 8ANC195 of the 
subunit interface category and with multiple antibodies of the CD4-binding site category; 
however, because glycan N276 is required for 8ANC195, and generally only accommodated by 
antibodies that target the CD4-binding site, we colored glycan N276 to be part of the subunit 
interface category. Left image is shown with viral membrane at bottom; right image is rotated 
90º to look down on the trimer apex. 
 
Fig. 2. Neutralization, B cell ontogeny, and paratope characteristics for 20 classes of 
broadly neutralizing antibodies. 
(A) The broadest neutralizing antibody from each class was chosen as representative. (B) 
Neutralization properties. Bar graphs show breadth and potency of each representative antibody 
on the 208-isolate panel, with dotted line showing averages. (C) Features of B cell ontogeny. 
CDR H3 lengths are defined based on Kabat nomenclature. @ indicates that antibody b12 is 
derived from a phage library. IOMA is the only antibody with CDHR H3 length under 20, SHM 
<12%, and breadth approaching 50%, and thus may be a promising candidate for lineage-based 
vaccine design. By contrast, VRC01-class antibodies have high SHM and PG9/PGT145 have 
unusually long CDR H3, complicating their lineage-based elicitation. (D) Paratope properties. 
“*” indicate structures determined in gp120-core context; “#” indicates structures determined 
with V1/V2 scaffold. Structures denoted with “*” or “#” were included in calculations of the 
category averages for protruding loop numbers, but not for paratope surface area. P-values were 
determined using two-tailed Mann-Whitney test. 
 
Fig. 3. Epitope features for 20 classes of broadly neutralizing antibodies. 
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(A) Categories, classes, and representative structures. “*” indicate structures determined in 
gp120-core context; “#” indicates structures determined with V1/V2 scaffold; @ indicates that 
the epitope structural variation of antibody 2G12 was not calculated due to the lack of protein 
epitope. Structures denoted with “*” or “#” were not included in calculations of the category 
averages for number of epitope segments and epitope total surface. Structures denoted with “*” 
were not included in calculations of the category average for epitope glycan composition. (B) 
Epitope properties. Bar graphs show conservation and glycan-interactive surface for each 
representative antibody, with dotted line showing averages. “*” indicate structures determined in 
gp120-core context, where glycan surface areas may not reflect trimer interactions. (C) Number 
of epitope segments, shown for segments with >25 Å2 or > 100 Å2 surface area. VRC34 has low 
number epitope segments and low glycan context (black arrow), and this may explain why fusion 
peptide immunization are yielding promising results from epitope-based vaccine design. (D) 
Observed variation in epitope structure, as calculated from RMSD of recognized amino acid 
residues, computed pairwise among class members of each category and unliganded trimer. (E) 
Prefusion-closed Env trimer colored by epitope and by various epitope features. P-values were 
determined using two-tailed Mann-Whitney test. 
 
Fig. 4. Correlations of neutralization and features of epitope and paratope reveal 
underlying relationships. 
Correlation matrices are shown for properties of neutralizing antibodies that recognize the 
prefusion closed Env trimer. (A) Pearson correlations (r) are provided in the upper right; P-
values (not adjusted for multiple comparisons) are provided in the lower left. Correlations with 
P-value of less than 0.06 were highlighted with dark red font, and correlations with P-value of 
less than 0.05 after Bonferroni correction were highlighted with both dark red font and orange 
fill. (B) Correlation between paratope surface area and epitope surface area. (C) Correlation 
between Epitope protein surface area and glycan component of surface. (D) Correlation between 
neutralizing breadth and heavy chain SHM. (E) Correlation between epitope conservation and 
epitope total surface area. 
 
Fig. 5. Factors affecting re-elicitation. 
(A) Categories, classes, and representative structures. (B) Recombination properties. Bar graphs 
show average VH gene frequency and paratope properties of D gene, N addition and CDR H3 
for each representative antibody. Average VH gene frequencies report from healthy donors in 
PRJNA304166. D gene and N additions occurring at the junctions are from IMGT V-quest 
(http://www.imgt.org/IMGT_vquest/vquest). # indicates that antibody missing nucleotide 
sequences at junction. (C) SHM likelihood. Bar graphs show the paratope contributed from SHM 
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(1st amino acid to the 2nd conserved Cys) and rare SHM. @ indicates that antibody missing 
nucleotide sequence. 
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Fig. 1. 20 classes of broadly neutralizing antibodies recognize the prefusion-closed Env
trimer and segregate into 6 categories based on the Env residues with which they interact. 
(A) All HIV-1 Env-antibody complexes structures in the PDB (Table S1) were assigned to classes 
(leftmost column, listed by the name of first reported antibody of the class) based on similarities in 
B cell ontogeny and mode of recognition, with a representative structure and PDB for the class 
(2nd and 3rd columns from left), which were chosen based on resolution and degree to which Env
in the structure resembled prefusion-closed trimer; “*” indicate structures determined in gp120-core 
context; “#” indicates structures determined with V1/V2 scaffold; ”@” indicates glycan N295, N332, 
and N392 used for 2G12 epitope (see methods) (B) Prefusion-closed Env trimer with molecular 
surface colored by categories defined in (A). Epitope residues shared by antibodies in separate 
classes were colored according to surface area and requirements for antibody binding. For 
example, glycan N276 has interactions with antibody 8ANC195 of the subunit interface category 
and with multiple antibodies of the CD4-binding site category; however, because glycan N276 is 
required for 8ANC195, and generally only accommodated by antibodies that target the CD4-
binding site, we colored glycan N276 to be part of the subunit interface category. Left image is 
shown with viral membrane at bottom; right image is rotated 90º to look down on the trimer apex.  
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Fig. 2. Neutralization, B cell ontogeny, and paratope characteristics for 20 classes  of 
broadly neutralizing antibodies. 
(A) The broadest neutralizing antibody from each class was chosen as representative. (B)
Neutralization properties. Bar graphs show breadth and potency of each representative antibody on 
the 208-isolate panel, with dotted line showing averages. (C) Features of B cell ontogeny. CDR H3 
lengths are defined based on Kabat nomenclature. @ indicates that antibody b12 is derived from a 
phage library. IOMA is the only antibody with CDHR H3 length under 20, SHM <12%, and breadth 
approaching 50%, and thus may be a promising candidate for lineage-based vaccine design. By 
contrast, VRC01-class antibodies have high SHM and PG9/PGT145 have unusually long CDR H3, 
complicating their lineage-based elicitation. (D) Paratope properties. “*” indicate structures 
determined in gp120-core context; “#” indicates structures determined with V1/V2 scaffold.  
Structures denoted with “*” or “#” were included in calculations of the category averages for 
protruding loop numbers, but not for paratope surface area.  P-values were determined using two-
tailed Mann-Whitney test.
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Fig. 3. Epitope features for 20 classes of broadly neutralizing antibodies. 
(A) Categories, classes, and representative structures. “*” indicate structures determined in gp120-
core context; “#” indicates structures determined with V1/V2 scaffold; @ indicates that the epitope 
structural variation of antibody 2G12 was not calculated due to the lack of protein epitope. 
Structures denoted with “*” or “#” were not included in calculations of the category averages for 
number of epitope segments and epitope total surface. Structures denoted with “*” were not 
included in calculations of the category average for epitope glycan composition. (B) Epitope 
properties. Bar graphs show conservation and glycan-interactive surface for each representative 
antibody, with dotted line showing averages. “*” indicate structures determined in gp120-core 
context, where glycan surface areas may not reflect trimer interactions. (C) Number of epitope 
segments, shown for segments with >25 Å2 or > 100 Å2 surface area. VRC34 has low number 
epitope segments and low glycan context (black arrow), and this may explain why fusion peptide 
immunization are yielding promising results from epitope-based vaccine design. (D) Observed 
variation in epitope structure, as calculated from RMSD of recognized  amino acid residues, 
computed pairwise among class members of each category and unliganded trimer. (E) Prefusion-
closed Env trimer colored by epitope and by various epitope features. P-values were determined 
using two-tailed Mann-Whitney test.
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Fig. 4. Correlations of neutralization and features of epitope and paratope reveal underlying 
relationships. 
Correlation matrices are shown for properties of neutralizing antibodies that recognize the 
prefusion closed Env trimer. (A) Pearson correlations (r) are provided in the upper right; P-values 
(not adjusted for multiple comparisons) are provided in the lower left. Correlations with P-value of 
less than 0.06 were highlighted with dark red font, and correlations with P-value of less than 0.05 
after Bonferroni correction were highlighted with both dark red font and orange fill. (B) Correlation 
between paratope surface area and epitope surface area. (C) Correlation between Epitope protein 
surface area and glycan component of surface. (D) Correlation between neutralizing breadth and 
heavy chain SHM. (E) Correlation between epitope conservation and epitope total surface area.
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Fig. 5. Factors affecting re-elicitation
(A) Categories, classes, and representative structures. (B) Recombination properties. Bar graphs 
show average VH gene frequency and paratope properties of D gene, N addition and CDR H3 for 
each representative antibody. Average VH gene frequencies report from healthy donors in 
PRJNA304166. D gene and N additions occurring at the junctions are from IMGT V-quest 
(http://www.imgt.org/IMGT_vquest/vquest). # indicates that antibody missing nucleotide sequences 
at junction. (C) SHM likelihood. Bar graphs show the  paratope contributed from SHM   (1st amino 
acid to the 2nd conserved Cys) and rare SHM. @ indicates that antibody missing nucleotide 
sequence.
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Table 1. Structural details for 20 classes of antibodies in complex with HIV-1 Env. 
Category  Class 
Antibody 
with most 
informative 
structure 
Most 
informa
tive 
PDB 
Experi
ment 
method 
Resol
ution 
(Å) 
Env 
component Epitope Residues 
V1V2  PGT145 PGT145 5V8L Cryo-
EM 
4.3 Trimer K121, T123, P124, V127, M161, T162, R166, D167, K169, I309, Q315, NAG608, T123, V127, 
N160, M161, T162, R166, D167, K168, K169, NAG606, NAG607, BMA608, K121, T123, P124, 
V127, N160, M161, T162, R166, D167, K168, K169, glycan 160  
 PG9 PG9 3U2S X-ray 1.8 Scaffolded 
V1V2  C157, S158, N160, T162, T163, K166, D167, R168, K169, Q170, K171, V172, N173, glycan 160, 
glycan 173 
 VRC38.01 VRC38.01 5VGJ X-ray 3.5 Scaffolded 
V1V2 region 
H130, T132, N133, V134, T135, I136, N156, C157, S158, F159, N160, K168, K171, E172, Y173, 
glycan 133, glycan 156, glycan 160 
Glycan-V3 PGT121 3H+109L 5CEZ X-ray 3.0 Trimer V134, T135, N136, A137, T139, D140, D321, I322, I323, G324, D325, I326, R327, Q328, H330, 
T415, P417, glycan 156, glycan 301, glycan 332 
 PGT128 PGT128 5ACO Cryo-
EM 
4.4 Trimer V134, T135, N136, N137, I138, L175, T297, P299, N301, D321, I322, I323, G324, D325, I326, 
R327, V442, R444, C445, glycan 156, glycan 301, glycan 332 
 PGT135 PGT135 4JM2 X-ray 3.1 gp120 P299, I323, G324, Q328, A329, H330, R335, M373, Y384, N386, Q389, T408, E409, T415, P417, 
C418, R419, K421, glycan 332, glycan 392, glycan 386 
 2G12 2G12 1OP5 X-ray 3.0 N-glycan 
Glycans 295, 332, 392 (Sanders et al. 2002 ) 
CD4-
binding 
site 
HJ16 HJ16 4YE4 X-ray 2.7 gp120 
T278, N279, N280, A281, T283, V360, Q362, P363, S364, S365, G366, G367, I371, T455, R456, 
D457, G458, G459, N460, N461, N462, K463, I469, R471, P472, G473, G474, D476, glycan 276 
 IOMA IOMA 5T3Z X-ray 3.5 Trimer K 97, E102, T198, T257, T278, N279, N280, A281, K282, R360, S365, G366, G367, D368, E370, 
V371, M426, W427, Q428, I430, T455, R456, D457, G458, G459, S460, T461, N462, S463, E466, 
T467, R469, G472, G473, D474, M475, R476,glycan 197, glycan 276, glycan 363, K 65, H 66, 
R308, glycan 262, glycan 301 
 8ANC131 CH235.09 5F9O X-ray 1.9 gp120 W 96, K 97, E275, N276, L277, T278, N279, N280, A281, K282, T283, S365, G366, G367, D368, 
I371, M426, G429, G431, Q432, T455, R456, D457, G458, G459, A460, N461, R469, P470, G471, 
G472, N474, D477, R480, glycan 276 
 VRC01 VRC01 5FYJ X-ray 3.1 Trimer W 96, K 97, V198, E275, N276, T278, D279, N280, A281, K282, T283, I360, S365, G366, G367, 
D368, I371, R425, Q428, R429, V455, R456, D457, G458, C459, K460, S461, T465, E466, T467, 
R469, A471, G472, G473, D474, R476, glycan 197, glycan 276, glycan 386, Y 61, S 62, E 64, 
glycan 301 
 VRC13.01 VRC13.01 4YDJ X-ray 2.3 gp120 W 96, K 97, E275, N279, N280, A281, K282, T283, R327, P364, S365, G366, G367, D368, L369, 
I371, T372, M373, Y384, K419, I420, K421, I423, T455, G458, G459, R469, P470, G471, G472, 
G473, N474, D477, R480, glycan 386 
 b12 b12 5VN8 Cryo-
EM 
3.6 Trimer K178, L179, V181, V182, P183, L184, E185, N185, K185, N185, N187, I188, T189, R192, I194, 
N195, N197, T198, S199, T257, N280, A281, H363, S364, S365, G366, G367, D368, P369, E370, 
I371, V372, T373, Y384, N386, Q417, C418, R419, K421, N425, M426, W427, Q428, G429, 
V430, G431, T455, R456, D457, R460, R469, G471, G472, G473, N474, M475, glycan 197, glycan 
362, glycan 386 
 CH103 CH103 4JAN X-ray 3.2 gp120 S256, D279, N280, A281, E362, H364, S365, G366, G367, D368, L369, E370, I371, T455, R456, 
D457, G458, G459, N460, D461, D462, N463, R469, P470, G471, G472 
 VRC16.01 VRC16.01 4YDK X-ray 2.1 gp120 Q105, L122, T123, G124, G198, S199, T257, E275, N280, A281, K282, T283, P364, S365, G366, 
G367, D368, L369, E370, I371, H375, N425, M426, W427, Q428, G429, G431, Q432, T455, R456, 
D457, G458, G459, A460, T463, T467, R469, P470, G471, G472, G473, N474, D477 
Silent face 
center 
VRC-PG05 VRC-PG05 6BF4 X-ray 2.4 gp120 N262, K290, S291, V292, E293, D334, E337, L446, S447, N448, glycan 262, glycan 295, glycan 
448 
Fusion 
peptide 
PGT151 PGT151 5FUU Cryo-
EM 
4.2 Trimer A 58, P 79, N 80, Q 82, E 83, V 84, V 85, A224, T244, V245, Q246, glycan 241,glycan 262, glycan 
295, glycan 448, A512, V513, G514, I515, G516, A517, V518, F519, G521, F522, R542, L543, 
S546, G547, V549, Q550, Q551, Q552, N553, N554, L592, N637, Y638, S640, E641, Y643, T644, 
E647, glycan 611, glycan 637 
 VRC34 VRC34.01 5I8H X-ray 4.3 Trimer N 80, Q 82, E 83, I 84, H 85, E 87, K229, D230, K231, S241, glycan 88, A512, V513, G514, I515, 
G516, A517, V518, F519, L520, G521, E648 
Subunit 
interface 
35O22 35O22 5CEZ X-ray 3.0 Trimer G527, S528, T529, A532, R617, N618, S620, E621, D624, N625, M626, T627, L629, Q630, K633, 
glycan 618, E 87, N 88, T 90, E 91, E 92, P238, P240, glycan 234, glycan 88 
 8ANC195 8ANC195 5CJX X-ray 3.6 Trimer S612, S613, W614, S615, N616, R617, M626, L629, Q630, D632, K633, E634, S636, N637, Y638, 
glycan 637, V 44, W 45, K 46, D 47, V 89, T 90, E 91, E 92, F 93, N 94, K 97, T236, G237, P238, 
E275, N276, I277, T278, K351, H352, F353, R456, K487, E492, glycan 234, glycan 276 
 
